REGENERON PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| Selling, general & administrative | $2.7B | $3.0B | $2.6B | $2.1B | $1.8B |
| Research and development | $5.9B | $5.1B | $4.4B | $3.6B | $2.9B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B |
| Interest expense | $43.8M | $55.2M | $73.0M | $59.4M | $57.3M |
| Pretax income | $5.2B | $4.8B | $4.2B | $4.9B | $9.3B |
| Income tax expense | $725.8M | $367.3M | $245.7M | $520.4M | $1.3B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B |
| Balance Sheet | |||||
| Cash and equivalents | $3.1B | $2.5B | $2.7B | $3.1B | $2.9B |
| Current assets | $18.0B | $18.7B | $19.5B | $15.9B | $14.0B |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B |
| Current liabilities | $4.4B | $3.9B | $3.4B | $3.1B | $3.9B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B |
| Stockholders' equity | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B |
| Cash Flow Statement | |||||
| Cash from operations | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Depreciation and amortization | $543.7M | $482.9M | $421.0M | $341.4M | $286.2M |
| Stock-based compensation | $993.7M | $982.8M | $885.0M | $725.0M | $601.7M |
| Capital expenditure | $898.4M | $755.9M | $718.6M | $590.1M | $551.9M |
| Free cash flow | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B |
| Dividends paid | $370.3M | $0 | $0 | — | — |
| Share repurchases | $3.4B | $2.6B | $2.2B | $2.1B | $1.6B |
Shares outstanding 104.8M · Free float 92.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.